Investigational drug · Phase 3
HFA-152a
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Asthma.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
11
Any phase or sponsor naming "HFA-152a"
First trial start
2025
Dec 17, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HFA-152a", any sponsor or status.
Conditions studied
As listed on its trial records.
- Asthma
Approved drugs for the same conditions: Asthma · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "HFA-152a" as an intervention, largest first.
- Comparison Between CHF5993 pMDI 200/6/12.5 µg HFA-152a VS CHF5993 pMDI 200/6/12.5 µg HFA-134a in Subjects With Asthma (TRECOS).Pivotal-lookingCompleted
Chiesi Farmaceutici S.p.A.Industry
NCT06264674 · 827 participants · Start Nov 27, 2023 · Primary completion Feb 18, 2025
Drug: CHF5993 200/6/12.5 μg pMDI HFA-152a; Inhaler CHF5993 200/6/12.5 μg pMDI HFA-134a · For: Asthma
Sites: Burgas, Bulgaria; Kozloduy, Bulgaria; Momchilgrad, Bulgaria · 118 sites in all
- Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate AsthmaPivotal-lookingRecruiting
Chiesi Farmaceutici S.p.A.Industry
NCT07301736 · 780 participants (planned) · Start Dec 17, 2025 · Primary completion Jun 3, 2027
Drug: CHF5993 pMDI with HFA-152a; CHF5993 pMDI with HFA-134a and 1 more · For: Asthma
Sites: Buenos Aires, Argentina; Ciudad Autonoma de Buenos Aire, Argentina; Córdoba, Argentina · 167 sites in all
- Safety and Efficacy Comparison Between CHF5993 100/6 12.5µg pMDI to Seretide Evohaler 125/25µg pMDI in Adolescent Subjects With AsthmaPivotal-lookingNot yet recruiting
Chiesi Farmaceutici S.p.A.Industry
NCT07858123 · 700 participants (planned) · Start Nov 16, 2026 · Primary completion Jun 26, 2030
Drug: CHF5993 100/6/12.5 μg pMDI HFA-152a; Seretide Evohaler · For: Asthma
Sites: Frankfurt, Germany; Göttingen, Germany; Jena, Germany · 25 sites in all
- Efficacy and Safety of CHF 5993 100/6/12.5 μg HFA-152a pMDI in Patients With Asthma Uncontrolled on Medium Doses of Inhaled Corticosteroids in Combination With Long-acting ß2-agonistsPivotal-lookingRecruiting
Chiesi Farmaceutici S.p.A.Industry
NCT07546981 · 554 participants (planned) · Start Jun 26, 2026 · Primary completion Oct 17, 2028
Drug: Experimental: Participant Group CHF 5993 pMDI HFA-152a · For: Asthma
Sites: Beijing, China · 2 sites in all
- A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With AsthmaPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT06261957 · 471 participants · Start May 31, 2024 · Primary completion Sep 2, 2025
Drug: Salbutamol HFA-134a; Salbutamol HFA-152a · For: Asthma
Sites: North Hollywood, California; San Mateo, California; Aventura, Florida · 102 sites in all
- A Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and HFA-1,1,1,2-tetrafluoroethane (134a)Pivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT07645248 · 110 participants (planned) · Start Sep 1, 2026 · Primary completion Dec 28, 2026
Drug: HFA-152a; HFA-134a · For: Asthma
Sites: Aventura, Florida; Miami, Florida; Naples, Florida · 20 sites in all
GlaxoSmithKlineGSK (GSK)
NCT06433921 · 84 participants (planned) · Start Aug 14, 2024 · Primary completion Apr 16, 2027
Drug: Salbutamol HFA-152a; Salbutamol HFA-134a and 1 more · For: Asthma; Mild Asthma
Sites: Manchester, United Kingdom
GlaxoSmithKlineGSK (GSK)
NCT06433908 · 60 participants · Start Jun 4, 2024 · Primary completion Oct 18, 2024
Drug: Salbutamol HFA-152a; Salbutamol HFA-134a · For: Asthma; Healthy Participants
Sites: Groningen, Netherlands
GlaxoSmithKlineGSK (GSK)
NCT05791565 · 28 participants · Start Apr 3, 2023 · Primary completion May 21, 2023
Drug: Salbutamol HFA-152a; Salbutamol HFA-134a · For: Asthma
Sites: Groningen, Netherlands
Chiesi Farmaceutici S.p.A.Industry
NCT05472662 · 25 participants · Start Aug 3, 2022 · Primary completion Oct 31, 2022
Drug: Placebo 152a; Placebo 134a · For: Asthma
Sites: Manchester, United Kingdom
Newest research
PubMed records naming it or its code names, newest first.
- Principles for a patient-centred transition to low-global warming potential pressurised metered-dose inhalers.
Halpin DM, Kaplan A, Field D, et al. · NPJ Prim Care Respir Med 2026
- Pharmaceutical assessment of low global warming potential alternatives to HFA-134a in a budesonide, glycopyrrolate, and formoterol fumarate pressurized metered-dose inhaler.
Lachacz K, Kaye R, Mello L, et al. · J Pharm Sci 2026
- Developing low-carbon metered-dose inhalers: effects of propellant HFA-152a on mucociliary clearance and bronchoconstriction in two Phase 1 randomised trials.
Singh D, Poggesi I, Weng S, et al. · Respir Med 2026
- Managing Inhaler Environmental Sustainability and Effective Respiratory Care: Current Evidence, Challenges, and Opportunities.
Booth A, Abbott J, Workman S, et al. · Pharmaceut Med 2026
- Switching to a Low Global Warming Potential Propellant in a Pressurized Metered-Dose Inhaler Does Not Affect the Pharmacokinetics of Combined Beclometasone Dipropionate/Formoterol Fumarate.
Almeida M, Salvadori M, Corradi M, et al. · Clin Ther 2026
- Toward Next-Generation Propellants: Assessing Lung Deposition of Beclometasone Dipropionate, Formoterol, and Glycopyrrolate Formulated with HFA-152a Using Functional Respiratory Imaging.
Matturro A, Monshi Tousi N, Sadafi H, et al. · J Aerosol Med Pulm Drug Deliv 2026
Also in development for Asthma
- CM512Phase 39 trials
Keymed Biosciences Co.Ltd · Chronic Rhinosinusitis With Nasal Polyposis, Chronic Spontaneous Urticaria (CSU), Asthma
- LunsekimigSAR443765Phase 39 trials
Sanofi · Asthma, Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps
- GSK5784283Phase 38 trials
GSK · Pulmonary Disease, Chronic Obstructive, Asthma, Nasal Polyps
- PF-07275315tilrekimigPhase 38 trials
Pfizer · Atopic Dermatitis, Asthma, Moderate to Severe Chronic Obstructive Pulmonary Disease
- MG-K10Humanized Monoclonal AntibodyPhase 36 trials
Shanghai Mabgeek Biotech.Co.Ltd · Dermatitis, Atopic, Chronic Urticaria, Idiopathic, Atopic Dermatitis
- SHR-1905Phase 36 trials
Guangdong Hengrui Pharmaceutical Co., Ltd · Asthma, Chronic Rhinosinusitis With Nasal Polyps, Moderate-to-severe Atopic Dermatitis
- TozorakimabMEDI3506Phase 36 trials
AstraZeneca · Chronic Obstructive Pulmonary Disease (COPD), Asthma, Viral Lung Infection and Acute Respiratory Failure
- TQC2731Phase 35 trials
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. · Asthma, Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from GSK.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.